By Michael Dabaie

 

Regeneron Pharmaceuticals Inc. (REGN) said results were positive from early-stage data for REGN1979 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

The company said there was a 93% overall response and 71% complete response rates in follicular lymphoma grades 1 to 3a treated with REGN1979 5 mg to 320 mg.

There was a 57% overall response rate in diffuse large B-cell lymphoma treated with REGN1979 80 mg to 160 mg, all of which were complete responses, including two complete responses in four patients whose disease had progressed after CAR-T treatment, the company said.

"We are very encouraged by the continued high response rates observed with REGN1979 in both relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, cancers with typically poor outcomes," said Israel Lowy, head of clinical and translational sciences, oncology at Regeneron.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

June 14, 2019 07:41 ET (11:41 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Regeneron Pharmaceuticals Charts.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Regeneron Pharmaceuticals Charts.